The new patent covers the methods of using vosaroxin at clinically relevant dose ranges and schedules for leukemia treatment.
Sunesis is now recruiting patients for Valor Phase 3 double-blind, randomized, placebo-controlled trial to evaluate vosaroxin in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.
Sunesis Pharma CEO Dan Swisher said the ‘468 patent adds another important facet to their global intellectual property estate for vosaroxin, providing significant coverage for uses of vosaroxin in the treatment of leukemia including the dose and schedule under evaluation in the pivotal, Phase 3 Valor trial.
"To supplement our granted patents, we have filed patent applications in territories around the world with claims covering additional vosaroxin formulations, combination uses, dosing, manufacturing processes and composition of matter claims, which may provide patent terms to 2030 when granted," Swisher said.